Preclinical News and Research

RSS
Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

Europe spends just 5% of total cancer research funds on metastases

Europe spends just 5% of total cancer research funds on metastases

U.S. Department of Defense OTT initiative to replace scars and defects with healthy, functional tissues

U.S. Department of Defense OTT initiative to replace scars and defects with healthy, functional tissues

NewYork-Presbyterian Hospital/Columbia University Medical Center announce presentations at American Urological Association meeting

NewYork-Presbyterian Hospital/Columbia University Medical Center announce presentations at American Urological Association meeting

Focused Ultrasound Surgery Foundation welcomes abstracts on MR-guided focused ultrasound

Focused Ultrasound Surgery Foundation welcomes abstracts on MR-guided focused ultrasound

HUYA Bioscience International forms strategic partnership with School of Chinese Materia Medica of BUCM

HUYA Bioscience International forms strategic partnership with School of Chinese Materia Medica of BUCM

Preimplantation Factor essential for pregnancy to succeed: Study

Preimplantation Factor essential for pregnancy to succeed: Study

Bioheart to establish two Centers of Excellence to provide cell therapy procedures for patients with CHF, PAD

Bioheart to establish two Centers of Excellence to provide cell therapy procedures for patients with CHF, PAD

Neptune's revenues increased by 8% for fiscal year ended February 28, 2010

Neptune's revenues increased by 8% for fiscal year ended February 28, 2010

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Regulus Therapeutics obtains rights to intellectual property covering methods for modulating microRNA-21

Regulus Therapeutics obtains rights to intellectual property covering methods for modulating microRNA-21

NOXXON Pharma closes €33 million Series D round of financing

NOXXON Pharma closes €33 million Series D round of financing

SonoSite signs agreement to acquire privately held Visualsonics

SonoSite signs agreement to acquire privately held Visualsonics

Shark cartilage extract shows no benefit for patients with advanced non-small cell lung cancer

Shark cartilage extract shows no benefit for patients with advanced non-small cell lung cancer

CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer

CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer

VisEn Medical announces launch of two new imaging agents at EMIM 2010

VisEn Medical announces launch of two new imaging agents at EMIM 2010

Gentium first-quarter net loss decreases to EUR 0.03 million

Gentium first-quarter net loss decreases to EUR 0.03 million

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.